Combination of KRASG12C and FGFR1 inhibitors as a resistance-overcoming therapeutic strategy for maximizing therapeutic impact of KRASG12C inhibitors

被引：0
|
作者：
Santos, Alba
Plaza, Patricia
Jimenez, Marta
Gomez-Sanchez, David
Paz-Ares, Luis
Ferrer, Irene
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-1930
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1930
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Preclinical efficacy of KRASG12C inhibitors in models of pediatric cancer
    Price, Hannah
    Stauffer, Stacey
    Powell, Katie
    Baker, Andrew
    Perciaccante, Andrew
    Hernandez, Edjay Ralph
    Odeniyide, Patience
    Pratilas, Christine
    Burgan, William
    Jenkins, Lisa
    Rossman, Kent L.
    Yohe, Marielle
    MOLECULAR CANCER RESEARCH, 2023, 21 (05)
  • [22] KRasG12C inhibitors in clinical trials: a short historical perspective
    Goebel, Lisa
    Mueller, Matthias P.
    Goody, Roger S.
    Rauh, Daniel
    RSC MEDICINAL CHEMISTRY, 2020, 11 (07): : 760 - 770
  • [23] Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer
    Blaquier, Juan Bautista
    Cardona, Andres Felipe
    Recondo, Gonzalo
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [24] Pemigatinib, an FGFR inhibitor, overcomes resistance to KRASG12C inhibitors in mesenchymal-like NSCLC tumors
    Favata, Margaret
    Weber, Michael
    Abdollahi, Angela
    Roman, Valerie Dostalik
    Farren, Matt
    Gilmartin, Aidan
    Kim, Sunkyu
    Wee, Susan
    Rios-Doria, Jonathan
    CANCER RESEARCH, 2023, 83 (07)
  • [25] Covalent inhibitors of the GTPase KRASG12C: a review of the patent literature
    Kettle, Jason G.
    Cassar, Doyle J.
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2020, 30 (02) : 103 - 120
  • [26] Characterization of Kinetic and Redox Properties of Oncogenic KRASG12C Inhibitors
    Campbell, Sharon
    FREE RADICAL BIOLOGY AND MEDICINE, 2023, 208 : S100 - S101
  • [27] The path to the clinic: a comprehensive review on direct KRASG12C inhibitors
    Albert K. Kwan
    Gary A. Piazza
    Adam B. Keeton
    Caio A. Leite
    Journal of Experimental & Clinical Cancer Research, 41
  • [28] TEAD Inhibitors Sensitize KRASG12C Inhibitors via Dual Cell Cycle Arrest in KRASG12C-Mutant NSCLC
    Tammaccaro, Salvina Laura
    Prigent, Philippe
    Le Bail, Jean-Christophe
    Dos-Santos, Odette
    Dassencourt, Laurent
    Eskandar, Myriam
    Buzy, Armelle
    Venier, Olivier
    Guillemot, Jean-Claude
    Veeranagouda, Yaligara
    Didier, Michel
    Spanakis, Emmanuel
    Kanno, Tokuwa
    Cesaroni, Matteo
    Mathieu, Stephane
    Canard, Luc
    Casse, Alhassan
    Windenberger, Fanny
    Calvet, Loreley
    Noblet, Laurence
    Sidhu, Sukhvinder
    Debussche, Laurent
    Moll, Jurgen
    Valtingojer, Iris
    PHARMACEUTICALS, 2023, 16 (04)
  • [29] The selective WEE1 inhibitor azenosertib shows synergistic anti-tumor activity with KRASG12C inhibitors in multiple KRASG12C models
    Jameson, Nathan M.
    Kim, Gabriel
    Lee, Catherine
    Skrable, Blake
    Shea, Alexandra
    Abed, Monah
    Harismendy, Olivier
    Ma, Jianhui
    Kim, Doris
    Lackner, Mark R.
    CANCER RESEARCH, 2024, 84 (06)
  • [30] Establishment and characterization of XPDX models with acquired or conditioned resistance to KRASG12C inhibitors
    Moriarty, A.
    Flores, J.
    Johnson, S.
    Cesenes, P.
    Graciano, G.
    Lund, J.
    Banos, N.
    Papadopoulos, K.
    Patnaik, A.
    Rasco, D.
    Moreno, V.
    DeMiguel, M.
    Wick, M.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S145 - S146
12345